|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2004-2-11
|
|
pubmed:abstractText |
The use of calcium- or aluminum-based phosphate binders against hyperphosphatemia is limited by the adverse effects of hypercalcemia or aluminum toxicity in long-term hemodialysis. Because nicotinamide is an inhibitor of sodium-dependent phosphate cotransport in rat renal tubule and small intestine, we examined whether nicotinamide reduces serum levels of phosphorus and intact parathyroid hormone (iPTH) in patients undergoing hemodialysis.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
0085-2538
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
65
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1099-104
|
|
pubmed:dateRevised |
2006-10-5
|
|
pubmed:meshHeading |
pubmed-meshheading:14871431-Aged,
pubmed-meshheading:14871431-Calcium,
pubmed-meshheading:14871431-Female,
pubmed-meshheading:14871431-Humans,
pubmed-meshheading:14871431-Hyperparathyroidism, Secondary,
pubmed-meshheading:14871431-Kidney Failure, Chronic,
pubmed-meshheading:14871431-Male,
pubmed-meshheading:14871431-Middle Aged,
pubmed-meshheading:14871431-NAD,
pubmed-meshheading:14871431-Niacinamide,
pubmed-meshheading:14871431-Parathyroid Hormone,
pubmed-meshheading:14871431-Phosphorus,
pubmed-meshheading:14871431-Phosphorus Metabolism Disorders,
pubmed-meshheading:14871431-Renal Dialysis
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Nicotinamide suppresses hyperphosphatemia in hemodialysis patients.
|
|
pubmed:affiliation |
Department of Medicine, Koto Hospital, Tokyo, Japan.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|
